Abstract
Caveolin (cav-1) and the GPI-anchored α-folate receptor (αFR) are membrane proteins both found associated to caveolar structures. Several studies in tumor cells independently reported cav-1 downregulation and αFR overexpression. Here we analysed the expression of the two molecules in normal and tumor ovarian samples derived from fresh specimens and from cultured cell lines. Whereas normal ovary surface epithelial cells displayed only cav-1 expression, ovarian tumor surgical samples and cell lines (COR, IGROV1, OVCAR3 and OVCA432) displayed high αFR and low-level or no cav-1 expression, except those cell lines (SKOV3 and SW626) with the lower αFR expression. SKOV3, but not two αFR-negative non-ovarian cell lines, exhibited downregulation of cav-1 expression following stable αFR cDNA transfection. Conversely, cav-1 transfection in IGROV1 cells led to downregulated αFR expression, together with formation of caveolar structures and reduction of growth capability. Moreover, cav-1 expression was induced in IGROV1 cells by transfection with intracellular anti-αFR antibodies to downmodulate αFR expression. In cav-1 transfected cells, transcriptional activity of the αFR-specific promoter P1 was reduced by 70% and an additional specific DNA-protein complex was identified by gel-shift assay, indicating that cav-1 expression influences αFR gene transcription. Together these results support the notion that αFR and cav-1 protein expression is reciprocally regulated in ovary cancer cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout








Similar content being viewed by others
References
Alberti S, Miotti S, Fornaro M, Mantovani L, Walter S, Canevari S, Ménard S and Colnaghi MI. . 1990 Biochem. Biophys. Res. Commun. 171: 1051–1055.
Anderson RGW. . 1998 Annu. Rev. Biochem. 67: 199–225.
Anderson RGW, Kamen BA, Rothberg KG and Lacey SW. . 1992 Science 255: 410–411.
Antony AC. . 1996 Annu. Rev. Nutr. 16: 501–521.
Bist A, Fielding PE and Fielding CJ. . 1997 Proc. Natl. Acad. Sci. USA 94: 10693–10698.
Bottero F, Tomassetti A, Canevari S, Miotti S, Ménard S and Colnaghi MI. . 1993 Cancer Res. 53: 5791–5796.
Coney LR, Tomassetti A, Carayannopoulos L, Frasca V, Kamen BA, Colnaghi MI and Zurawski Jr. VR. . 1991 Cancer Res. 51: 6125–6132.
Couet J, Li SW, Okamoto T, Ikezu T and Lisanti MP. . 1997a J. Biol. Chem. 272: 6525–6533.
Couet J, Sargiacomo M and Lisanti MP. . 1997b J. Biol. Chem. 272: 30429–30438.
Elwood PC, Nachmanoff K, Saikawa Y, Page ST, Pacheco P, Roberts S and Chung K-N. . 1997 Biochemistry 36: 1467–1478.
Engelman JA, Lee RJ, Karnezis A, Bearss DJ, Webster M, Siegel P, Muller WJ, Windle JJ, Pestell RG and Lisanti MP. . 1998a J. Biol. Chem. 273: 20448–20455.
Engelman JA, Wykoff CC, Yasuhara S, Song KS, Okamoto T and Lisanti MP. . 1997 J. Biol. Chem. 272: 16374–16381.
Engelman JA, Zhang XL and Lisanti MP. . 1998b FEBS Lett. 436: 403–410.
Engelman JA, Zhang XL and Lisanti MP. . 1999a FEBS Lett. 448: 221–230.
Engelman JA, Zhang XL, Razani B, Pestell G and Lisanti MP. . 1999b J. Biol. Chem. 274: 32333–32341.
Figini M, Obici L, Mezzanzanica D, Griffiths AD, Colnaghi MI, Winter G and Canevari S. . 1998 Cancer Res. 58: 991–996.
Hulit J, Bash T, Fu M, Galbiati F, Albanese C, Sage DR, Schlegel A, Zhurisky J, Shtutman M, Ben-Ze'ev A, Lisanti MP and Pestell RG. . 2000 J. Biol. Chem. 275: 21203–21209.
Koleske AJ, Baltimore D and Lisanti MP. . 1995 Proc. Natl. Acad. Sci. USA 92: 1381–1385.
Kruk PA, Maines-Bandiera SL and Auersperg N. . 1990 Lab. Invest. 63: 132–136.
Lee SW, Reimer CL, Oh P, Campbell DB and Schnitzer JE. . 1998 Oncogene 16: 1391–1397.
Li SW, Couet J and Lisanti MP. . 1996 J. Biol. Chem. 271: 29182–29190.
Miotti S, Bagnoli M, Ottone F, Tomassetti A, Colnaghi MI and Canevari S. . 1997 J. Cell. Biochem. 65: 479–491.
Miotti S, Bagnoli M, Tomassetti A, Colnaghi MI and Canevari S. . 2000 J. C. Sci. 113: 349–357.
Miotti S, Canevari S, Ménard S, Mezzanzanica D, Porro G, Pupa SM, Regazzoni M, Tagliabue E and Colnaghi MI. . 1987 Int. J. Cancer 39: 297–303.
Miotti S, Facheris P, Tomassetti A, Bottero F, Bottini C, Ottone F, Colnaghi MI, Bunni MA, Priest DG and Canevari S. . 1995 Int. J. Cancer 63: 395–401.
Murata M, Peränen J, Schreiner R, Wieland F, Kurzchalia TV and Simons K. . 1995 Proc. Natl. Acad. Sci. USA 92: 10339–10343.
Okamoto T, Schlehel A, Scherer PE and Lisanti MP. . 1998 J. Biol. Chem. 273: 5419–5422.
Ottone F, Miotti S, Bottini C, Bagnoli M, Perego P, Colnaghi MI and Ménard S. . 1997 Br. J. Cancer 76: 77–82.
Persic L, Righi M, Roberts A, Hoogenboom HR, Cattaneo A and Bradbury A. . 1997 Gene 187: 1–8.
Racine C, Belanger M, Hirabayashi H, Boucher M, Chakir J and Couet J. . 1999 Biochem. Biophys. Res. Commun. 255: 580–586.
Rothberg KG, Heuser E, Donzell WC, Ying Y-S, Glenney Jr. JR and Anderson RGW. . 1992 Cell 68: 673–682.
Saikawa Y, Price K, Hance KW, Chen TY and Elwood PC. . 1995 Biochemistry 34: 9951–9961.
Scherer PE, Lewis RY, Volonté D, Engelman JA, Galbiati F, Couet J, Kohtz DS, Van Donselaar E, Peters P and Lisanti MP. . 1997 J. Biol. Chem. 272: 29337–29346.
Scherer PE, Okamoto T, Chun MY, Nishimoto I, Lodish HF and Lisanti MP. . 1996 Proc. Natl. Acad. Sci. USA 93: 131–135.
Simons K and Ikonen E. . 1997 Nature 387: 569–572.
Smart EJ, Ying Y-S, Conrad PA and Anderson RGW. . 1994 J. Cell Biol. 127: 1185–1197.
Tang ZL, Scherer PE, Okamoto T, Song K, Chu C, Kohtz DS, Nishimoto I, Lodish HF and Lisanti MP. . 1996 J. Biol. Chem. 271: 2255–2261.
Toffoli G. Cernigoi C, Russo A, Gallo A, Bagnoli M and Boiocchi M. . 1997 Int. J. Cancer 74: 193–198.
Acknowledgements
We thank Dr PC Elwood for kindly providing the P1- and P4-CAT constructs and Dr F Mangiarotti for his helpful suggestions. We also thank Mrs A Filippini for technical assistance, Mrs A Cipollina for assistance in preparing the manuscript and Mr M Azzini for photographic reproductions. This work was supported by grants from the Italian Association for Cancer Research (AIRC). M Bagnoli is a recipient of an AIRC/FIRC fellowship.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bagnoli, M., Tomassetti, A., Figini, M. et al. Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to α-folate receptor overexpression. Oncogene 19, 4754–4763 (2000). https://doi.org/10.1038/sj.onc.1203839
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.onc.1203839
Keywords
This article is cited by
-
Choline kinase alpha impairment overcomes TRAIL resistance in ovarian cancer cells
Journal of Experimental & Clinical Cancer Research (2021)
-
Combined and selective miR-21 silencing and doxorubicin delivery in cancer cells using tailored DNA nanostructures
Cell Death & Disease (2021)
-
Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma
British Journal of Cancer (2003)
-
Peroxisome proliferator-activated receptor-γ upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells
Oncogene (2003)
-
Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies
Gene Therapy (2003)


